Skip to content

Homoeopathic treatment with therapy for Pain Management in Cancer Patients.

Homoeopathic treatment as an add-on therapy for Pain Management in Cancer Patients: A Prospective, Randomized, Exploratory study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060290
Enrollment
450
Registered
2023-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site

Interventions

Intervention1: HOMEOPATHIC INTERVENTION: Patients shall be prescribed a known Pharmacopeial homeopathic medicine based on the totality of symptoms by the homeopathic investigator as an add-on to the s

Sponsors

Central Council for Research in Homeopathy Ministry Ministry of Ayush
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults of either gender aged between 18 to 75 years. Numeric Rating Score (NRS) for pain assessment = 4 Pain related to tumour, treatment or unrelated to both Patients requiring non-opioids (NSAID); mild opioids (tramadol); strong opioids (morphine) in sequential order as per World Health Organization (WHO) Pain Relief Ladder.

Exclusion criteria

Exclusion criteria: Cases requiring neurosurgical procedures such as brain stimulators, nerve blocks, intrathecal drug delivery systems and neurolysis Inability to comply with the study protocol, including psychiatric disease

Design outcomes

Primary

MeasureTime frame
To compare the scores of NRS in both the arms of add-on homoeopathic intervention to standard care treatment and stand-alone care treatment at baseline, 7 days and subsequently fortnightly for 3 months.Timepoint: 1 year

Secondary

MeasureTime frame
To assess the changes in the symptoms common in cancer patients using ESAS-R in both the arms at baseline, 7 days and subsequently fortnightly for 3 months. To assess the quality of life using EORTC QLQ-C30 in both the arms at baseline, 7 days and subsequently fortnightly for 3 months.Timepoint: 1 year

Countries

India

Contacts

Public ContactDr Chetna Deep Lamba

All India Institute of Medical Sciences (AIIMS)

sushmabhatnagar1@gmail.com9811326453

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026